Article Text

PDF
▼Etanercept and ▼infliximab for rheumatoid arthritis

Abstract

&#9660Etanercept* (Enbrel - Wyeth) and&#9660infliximab* (Remicade - Schering Plough) belong to a new class of drugs that block the effects of tumour necrosis factor-alpha (TNF-α), a mediator of inflammation. Both are licensed for the treatment of patients with active rheumatoid arthritis who have responded inadequately to disease-modifying antirheumatic drugs (DMARDs). Here, we consider whether etanercept and infliximab offer advantages.

Statistics from Altmetric.com

  • Relevant BNF section: 10.1.3

View Full Text

Footnotes

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.